Under Armour buys MyFitnessPal, Endomondo for $560 million

Neil Versel | | Health Exec | Economics

Sports apparel maker Under Armour is continuing its push into the quantification of fitness and health with the acquisition of fitness apps MyFitnessPal for $475 million and Endomondo for $85 million. The Baltimore-based company had bought MapMyFitness in 2013 and introduced its own app, UA Record, at International CES last month. 

As the Baltimore Sun reports, UA Record is intented to be a data dashboard for the other three products—as well as the Armour39 sports biometric sensor—which will be marketed collectively as Connected Fitness. MyFitnessPal in particular is sitting on a large storehouse of data from its 80 million registered users.

Under Armour to buy two fitness apps as it builds online community

Neil Versel

Neil Versel joined TriMed in 2015 as the digital editor of Clinical Innovation + Technology, after 11 years as a freelancer specializing in health IT, healthcare quality, hospital/physician practice management and healthcare finance.

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.